arrow
F

Francesca Romana Di Pietro

idi-irccs
H指数:18
被引数:1,429

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immune-Related Adverse Events in Patients with Melanoma Treated with B-RAF/MEK Target Therapy: Occurrence and Circulating Immune Cell Analysis

黑色素瘤患者接受B-RAF/MEK靶向治疗后出现的免疫相关不良事件:发生情况及循环免疫细胞分析

Cancers
IF4.4
2026-04-030
OAAI
Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience
2024-10-011
OAAI
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

肝细胞癌患者与其他晚期实体瘤患者免疫治疗相关肝损伤的特征和结局

2024-03-0111
OA
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
2024-02-010
PRE
Medium to long-term effects of the COVID-19 pandemic on colorectal cancer diagnosis and management in Italy: Preliminary findings from an updated analysis of the real-world multicenter COVID-DELAY study
2023-10-010
PRE
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, Real-Life, Case-Control Study

在左侧RAS和BRAF野生型转移性结直肠癌患者中,临床医生对双联加抗EGFR与三联加贝伐单抗作为一线治疗的态度: 一项多中心,现实生活,病例对照研究

2021-12-017
PRE
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
2021-10-275
OAAI
Merkel Cell Carcinoma

默克尔细胞癌

2021-06-2314
OAAI
Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients

可溶性免疫检查点,肠道代谢物和性能状态作为NSCLC患者对Nivolumab治疗的反应参数

2020-11-0428
OAAI
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study
2020-07-0151
OAAI
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy

转移部位在预测免疫治疗癌症患者预后中的不可知作用

2020-04-2847
OAAI
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice
2019-11-1523
OAAI